ArticleDiscover oncology2026
Tumor location and morphological MRI features in relation to combined 1p/22q deletion in meningioma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombined chromosomal 1p/22q deletion is associated with aggressive tumor biology and an increased risk of recurrence in meningiomas. Since C-IMPACT-NOW Update 8, this molecular alteration has gained relevance in the stratification of WHO grade 2 tumors. However, reliable preoperative predictors of combined 1p/22q deletion remain limited. The present study aimed to identify clinical and radiological predictors of combined 1p/22q deletion in meningiomas.
methodsIn this retrospective single-center study, 197 patients with histopathologically confirmed meningiomas and available chromosomal status were analyzed. Preoperative MRI-based tumor characteristics, including tumor volume, surface area, roundness, flatness, and length of dural attachment, were assessed on gadolinium-enhanced T1-weighted MRI. Tumor volumetry was performed using the SmartBrush tool within the BrainLAB software (BrainLAB, Munich, Germany) via a semi-automatic segmentation flow. Surface area, roundness and flatness were derived using the open-source software 3D Slicer. Optimal cut-off values were determined using receiver operating characteristic (ROC) curve analysis with the Youden index. Variables were evaluated using uni- and multivariable analyses. Anatomical subgroup analysis was performed in non-skull base (NSB) meningiomas.
resultsIn the overall cohort, NSB location was independently associated with combined 1p/22q deletion (OR 3.267, 95% CI 1.012-10.545; p = 0.048). In the NSB subgroup (n = 102), tumor volume (p = 0.027), tumor surface area (p = 0.020), and length of dural attachment (p = 0.042) were significantly associated with combined 1p/22q deletion in univariate analyses.
conclusionNSB meningiomas are independently associated with combined 1p/22q deletion. Quantitative and anatomically interpretable MRI-based tumor characteristics, particularly in NSB tumors, may provide supplementary information for preoperative risk stratification. These characteristics may contribute to decision-making process and identifying those necessitating surgery due to potential aggressive biological behavior.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.